BITMINE IMMERSION TECHNOLOGIES, INC. (BMNR)
Bitmine Immersion Technologies annonce les premiers dividendes et la cotation au NYSE de ses actions privilégiées de série A
BITMINE IMMERSION TECHNOLOGIES, INC. (BMNR)
Bitmine Immersion Technologies kondigt initiële dividenden en een NYSE-notering aan voor Series A Preferred Stock
NANO-X IMAGING LTD. (NNOX)
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with the Schall Law Firm
MICROSOFT CORP (MSFT)
MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit with the Schall Law Firm
ASCENDIS PHARMA A/S (ASND)
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
GENMAB A/S (GMAB)
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
GENMAB A/S (GMAB)
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
INCYTE CORP (INCY)
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
ELI LILLY & CO (LLY)
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
Eli Lilly and Company (LLY)
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting